Trials / Completed
CompletedNCT00984919
Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers
Pilot Study of the Role of 11-dh-TXB2 in Prostate Cancer Screening and Diagnosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Barbara Ann Karmanos Cancer Institute · Academic / Other
- Sex
- Male
- Age
- 40 Years – 120 Years
- Healthy volunteers
- Accepted
Summary
RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at a biomarker, 11-dh-TXB2, in blood and urine samples from patients with prostate cancer and healthy volunteers.
Detailed description
OBJECTIVES: * To identify a potential novel marker of prostate cancer in the blood and urine, 11-dh-TXB2, to be used as a screening tool for prostate cancer as well as in detection of early relapse in patients previously treated for early-stage prostate cancer. OUTLINE: Blood and urine samples are collected and analyzed for plasma and urinary 11-dh-TXB2 levels by HPLC and tandem-mass spectrometry.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | high performance liquid chromatography | |
| OTHER | laboratory biomarker analysis | |
| OTHER | mass spectrometry |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-01-01
- Completion
- 2011-02-01
- First posted
- 2009-09-25
- Last updated
- 2016-02-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00984919. Inclusion in this directory is not an endorsement.